The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

William M. Drake

Department of Endocrinology

St. Bartholomew 's Hospital

London

UK

[email]@qmul.ac.uk

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Endocrinology, St. Bartholomew 's Hospital, London, UK. 2002 - 2005
  • Osteoporosis Research Centre, University of British Columbia, Vancouver, British Columbia, Canada. 2003

References

  1. Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomant. Drake, W.M., Loureiro, R.A., Parkinson, C., Monson, J.P., Besser, G.M., Trainer, P.J. Eur. J. Endocrinol. (2005) [Pubmed]
  2. Markers of cell proliferation in a GH-producing adenoma of a patient treated with pegvisomant. Drake, W.M., Berney, D.M., Kovacs, K., Monson, J.P. Eur. J. Endocrinol. (2005) [Pubmed]
  3. The effect of cessation of growth hormone (GH) therapy on bone mineral accretion in GH-deficient adolescents at the completion of linear growth. Drake, W.M., Carroll, P.V., Maher, K.T., Metcalfe, K.A., Camacho-Hübner, C., Shaw, N.J., Dunger, D.B., Cheetham, T.D., Savage, M.O., Monson, J.P. J. Clin. Endocrinol. Metab. (2003) [Pubmed]
  4. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Drake, W.M., Rowles, S.V., Roberts, M.E., Fode, F.K., Besser, G.M., Monson, J.P., Trainer, P.J. Eur. J. Endocrinol. (2003) [Pubmed]
  5. An investigation of the predictors of bone mineral density and response to therapy with alendronate in osteoporotic men. Drake, W.M., Kendler, D.L., Rosen, C.J., Orwoll, E.S. J. Clin. Endocrinol. Metab. (2003) [Pubmed]
  6. Skeletal consequences of discontinuation of growth hormone at final height. Drake, W.M., Carroll, P.V., Savage, M.O., Monson, J.P. J. Pediatr. Endocrinol. Metab. (2002) [Pubmed]
 
WikiGenes - Universities